NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free ALGS Stock Alerts $0.78 -0.04 (-4.87%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.77▼$0.8350-Day Range$0.64▼$1.1352-Week Range$0.54▼$1.38Volume110,840 shsAverage Volume302,645 shsMarket Capitalization$59.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Aligos Therapeutics alerts: Email Address Aligos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.87% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.92Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.31 out of 5 starsMedical Sector322nd out of 913 stocksBiological Products, Except Diagnostic Industry40th out of 152 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Aligos Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.87% of the outstanding shares of Aligos Therapeutics have been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently decreased by 24.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aligos Therapeutics is -0.80. Previous Next 2.7 News and Social Media Coverage News SentimentAligos Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aligos Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($0.83) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insiders4 coins to be the “Next Bitcoin”The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Aligos Therapeutics Stock (NASDAQ:ALGS)Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More ALGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALGS Stock News HeadlinesApril 25, 2024 | globenewswire.comAligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyApril 25, 2024 | finance.yahoo.comAligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDApril 28, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | finance.yahoo.comAligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024April 3, 2024 | finance.yahoo.comAligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsMarch 27, 2024 | globenewswire.comAligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesMarch 16, 2024 | uk.investing.comAligos Therapeutics Inc (ALGS)March 15, 2024 | markets.businessinsider.comMaintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics’ Clinical PipelineApril 28, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 14, 2024 | finance.yahoo.comAligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2024 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | benzinga.comRecap: Aligos Therapeutics Q4 EarningsMarch 12, 2024 | globenewswire.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsMarch 8, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)March 6, 2024 | seekingalpha.comTracking Baker Brothers Portfolio - Q4 2023 UpdateMarch 5, 2024 | globenewswire.comAligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024February 26, 2024 | globenewswire.comAligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024February 24, 2024 | msn.comAligos Therapeutics (ALGS) Price Target Increased by 300.00% to 4.08February 23, 2024 | benzinga.comAligos Therapeutics Stock (NASDAQ:ALGS) Earnings Dates and Earning CallsFebruary 23, 2024 | benzinga.comAligos Therapeutics Stock (NASDAQ:ALGS), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comAligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024February 20, 2024 | globenewswire.comAligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024February 19, 2024 | finance.yahoo.comAligos Therapeutics, Inc. (ALGS)February 15, 2024 | investing.comAligos Therapeutics bolsters executive team with new VPsFebruary 13, 2024 | finance.yahoo.comAligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsFebruary 10, 2024 | msn.comAligos Therapeutics in portfolio reorganization focused on NASH, COVID assetsJanuary 26, 2024 | msn.comAligos Therapeutics Launches Voluntary Option Exchange ProgramSee More Headlines Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALGS CUSIPN/A CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,680,000.00 Net Margins-607.03% Pretax Margin-559.49% Return on Equity-116.41% Return on Assets-75.38% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$15.53 million Price / Sales3.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.64Miscellaneous Outstanding Shares75,670,000Free Float63,184,000Market Cap$59.17 million OptionableOptionable Beta2.34 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Lawrence M. Blatt MBA (Age 62)Ph.D., CEO, President & Chairman of the Board Comp: $832.73kDr. Julian A. Symons DPHIL (Age 62)Executive VP & Chief Scientific Officer Comp: $618.66kMs. Lesley Ann Calhoun CPA (Age 58)Executive VP & CFO Kristina EngesethVP and Head of People & CultureDr. Matthew W. McClure M.D. (Age 52)Executive VP & Chief Medical Officer Dr. Sushmita M. Chanda DABT (Age 57)Ph.D., Executive Vice President & Chief Development Officer Dr. David B. Smith Ph.D.Executive VP & Head of Chemical OperationsDr. Tse-I Lin Ph.D.VP of Early Compound Development & Belgian Site HeadMore ExecutivesKey CompetitorsEntera BioNASDAQ:ENTXJATT AcquisitionNYSE:JATTIkena OncologyNASDAQ:IKNAGenenta ScienceNASDAQ:GNTALENZ TherapeuticsNASDAQ:LENZView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 1,297,000 shares on 2/15/2024Ownership: 1.731%Altitude Crest Partners Inc.Bought 2,844,681 shares on 2/14/2024Ownership: 3.796%Hhlr Advisors LTD.Sold 403,573 shares on 2/14/2024Ownership: 2.544%Armistice Capital LLCBought 6,833,875 shares on 2/13/2024Ownership: 9.120%Carole NuechterleinBought 7,933,601 shares on 10/25/2023Total: $6.03 M ($0.76/share)View All Insider TransactionsView All Institutional Transactions ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed in 2024? Aligos Therapeutics' stock was trading at $0.6640 at the beginning of 2024. Since then, ALGS stock has increased by 17.8% and is now trading at $0.7820. View the best growth stocks for 2024 here. Are investors shorting Aligos Therapeutics? Aligos Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 657,200 shares, a decrease of 24.4% from the March 31st total of 868,800 shares. Based on an average daily trading volume, of 388,300 shares, the days-to-cover ratio is presently 1.7 days. View Aligos Therapeutics' Short Interest. When is Aligos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALGS earnings forecast. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) posted its earnings results on Tuesday, March, 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The firm earned $2.68 million during the quarter, compared to the consensus estimate of $3.20 million. Aligos Therapeutics had a negative trailing twelve-month return on equity of 116.41% and a negative net margin of 607.03%. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALGS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
